An observational study in Evaluation of the Relationship Between Serum Biomarkers (Endocan and ADMA) and Penile Doppler Ultrasonography Findings of Patients With Severe Erectile Dysf, sponsored by Ankara Etlik City Hospital. Completed at 1 site in Turkey. Open to male participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-08-07.
Sponsored by Ankara Etlik City Hospital · Observational
The gold standard diagnosis in patients admitted to the hospital with the complaint of erectile dysfunction is penile doppler ultrasonography. This procedure is an invasive procedure and can cause various complications. Therefore, in this study, we aimed to support and define the diagnosis of erectile dysfunction with some biomarkers that can be measured in blood samples. At this point, we performed penile doppler ultrasonography, which is the gold standard test, for all patients who applied with the complaint of erectile dysfunction, and compared the results of penile doppler and serum biomarkers in the patients.
683 studies on the registry are indexed under Erectile Dysfunction; 117 are open to participants now.
This study's enrollment of 73 is below the median of 130 across 115 observational studies indexed under Erectile Dysfunction.
Browse Erectile Dysfunction studies →Ankara Etlik City Hospital is the lead sponsor of 166 studies on the registry; 75 are open to participants now.
Counted across the registry records on this site, refreshed daily.
tertiary care clinic
Exclusion Criteria:
To evaluate the relationship between serum endocan (endothelial cell-specific molecule-1), ADMA (asymmetric dimethylarginine) values and penile Doppler ultrasonography findings in patients with severe Erectile dysfunction.
Time frame: 10 days from the outpatient clinic admission
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ankara Etlik City Hospital